AAAAAA
Results:
1-15
|
Results: 15
Authors:
Neven, P
Vergote, G
Citation: P. Neven et G. Vergote, Tamoxifen, screening and new oestrogen receptor modulators, BEST P R CL, 15(3), 2001, pp. 365-380
Authors:
de Leval, X
Delarge, J
Devel, P
Neven, P
Michaux, C
Masereel, B
Pirotte, B
David, JL
Henrotin, Y
Dogne, JM
Citation: X. De Leval et al., Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood, PROS LEUK E, 64(4-5), 2001, pp. 211-216
Authors:
Goldstein, SR
Neven, P
Zhou, LF
Taylor, YL
Ciaccia, AV
Plouffe, L
Citation: Sr. Goldstein et al., Raloxifene effect on frequency of surgery for pelvic floor relaxation, OBSTET GYN, 98(1), 2001, pp. 91-96
Authors:
Vergote, I
Neven, P
van Dam, P
Serreyn, R
De Prins, F
De Sutter, P
Albertyn, G
Citation: I. Vergote et al., The oestrogen receptor and its selective modulators in gynaecological and breast cancer, EUR J CANC, 36, 2000, pp. S1-S9
Authors:
Neven, P
Citation: P. Neven, Oestrogen and female cancers: the past 100 years, EUR J CANC, 36, 2000, pp. S13-S14
Authors:
Gordts, SL
Neven, P
Van Hooff, I
Tonglet, R
Laurent, C
Marechal, S
De Muylder, X
Van Belle, Y
Vanderick, G
Citation: Sl. Gordts et al., The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue, EUR J CANC, 36, 2000, pp. S20-S21
Authors:
Carmichael, PL
Pole, JCM
Neven, P
Citation: Pl. Carmichael et al., Modulation of endometrial transforming growth factor beta (TGF beta) by tamoxifen, EUR J CANC, 36, 2000, pp. S42-S43
Authors:
Neven, P
Citation: P. Neven, Other selective oestrogen receptor modulators (SERMs) in development, EUR J CANC, 36, 2000, pp. S65-S66
Authors:
Dogne, JM
de Leval, X
Neven, P
Rolin, S
Wauters, J
David, JL
Delarge, J
Masereel, B
Citation: Jm. Dogne et al., Effects of a novel non-carboxylic thromboxane A(2) receptor antagonist (BM-531) derived from torasemide on platelet function, PROS LEUK E, 62(5), 2000, pp. 311-317
Authors:
Neven, P
Citation: P. Neven, Local levonorgestrel to prevent tamoxifen-related endometrial lesions, LANCET, 356(9243), 2000, pp. 1698-1699
Authors:
Neven, P
Vernaeve, H
Citation: P. Neven et H. Vernaeve, Guidelines for monitoring patients taking tamoxifen treatment, DRUG SAFETY, 22(1), 2000, pp. 1-11
Authors:
Neven, P
Citation: P. Neven, The effect of SERMs on the reproductive system, SERMS: A NOVEL OPTION TO MAINTAIN HEALTH IN THE POSTMENOPAUSE, 2000, pp. 103-119
Authors:
Carmichael, PL
Sardar, S
Crooks, N
Neven, P
Van Hoof, I
Ugwumadu, A
Bourne, T
Tomas, E
Hellberg, P
Hewer, AJ
Phillips, DH
Citation: Pl. Carmichael et al., Lack of evidence from HPLC P-32-post-labelling for tamoxifen-DNA adducts in the human endometrium, CARCINOGENE, 20(2), 1999, pp. 339-342
Authors:
Neven, P
Citation: P. Neven, SERMs: the stage is set for testing in oestrogen-related cancer survivors, 7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, pp. 115-120
Authors:
Pirotte, B
de Tullio, P
Podona, T
Diouf, O
Dewalque, D
Neven, P
Masereel, B
Caignard, DH
Renard, P
Delarge, J
Citation: B. Pirotte et al., Pyridothiadiazinedioxides structurally related to quinazolinones cholecystokinin gastrin receptor ligands: synthesis and biological evaluation, EUR J PH SC, 7(1), 1998, pp. 29-40
Risultati:
1-15
|